Merck
Search Within
应用
内容物类型

Cell culture for manufacturing

应用筛选条件
facet applications:Cell culture for manufacturing
facet content type:Technical Article
显示 1-10 共 10 条结果
CHO平台
我们开发了多种工具,可让您比以往更快、更轻松地为您特定的CHO克隆开发优化的培养基配方。
蛋白质表达系统
基因工程和克隆的发展为研究领域开辟了表达和分离异源蛋白质的许多可能性。技术上巨大进步使得能够大规模表达和分离重组蛋白。
EX-CELL® Glycosylation Adjust (GAL+)
Our protein quality supplement, EX-CELL® Glycosylation Adjust (Gal+), provides customers with a novel chemically defined product which targets glycosylation attributes.
EX-CELL® Advanced™ CHO Fed-Batch System – Bioprocessing Technology Institute, Singapore Case Study
In this study, nine commercially available, chemically defined media and feed combinations from different vendors were assessed for producing monoclonal antibody in Chinese hamster ovary (CHO) cells.
Speeding Biosimilar Development using Glycosylation Control Technology from SAFC
The biosimilar market is expected to grow rapidly in the coming years, as many blockbuster monoclonal antibodies lose patent protection by 2020.
Protein Expression Systems
The development of genetic engineering and cloning has opened many possibilities of expression and isolation of heterologous proteins for research purposes. Considerable advances in technology have enabled expression and isolation of recombinant proteins in large scale.
Using Microarray Technology to Select Housekeeping Genes in Chinese Hamster Ovary Cells
In the present study, we have identifi ed species-specifi c housekeeping genes (HKGs) for Chinese Hamster Ovary (CHO) cells using data from microarray gene expression profiling.
CHO Platform
We have developed a number of tools that allow you to develop optimized media formulations for your specific CHO clones faster and easier than ever before.
Modified Amino Acids
Modified amino acids are inhouse manufactured amino acid derivatives with specific properties enabling the intensification of cell culture processes.
Quantification of Host Cell Proteins
Residual presence of host cell proteins (HCPs) in recombinant therapeutic products has considerable clinical safety risks associated with a potential immunological response in patients.